Mohit Trikha

Mohit (Mo) Trikha is a venture partner at ATP. Prior to ATP, Mo was vice president and head of Oncology Early Development at AbbVie and the site head of AbbVie Bay Area. At AbbVie, he was accountable for advancing oncology discovery stage programs up to clinical proof of concept and led a team of project leaders, project managers, clinical scientists, clinicians, biologics manufacturing specialists, and regulatory experts. His portfolio of assets included small molecules, bispecifics, ADCs, IO and CAR-T cell therapies. He was a core member of oncology business development committees, chaired AbbVie’s Oncology Early Development Review Committee, and led multiple external joint governance collaborations with TeneoBio, Trishula, Calibr, and Jacobio, as well as a multi-therapeutic collaboration with Scripps Research. He also served on the board of California Life Sciences. Prior to AbbVie, Mo was president, chief scientific officer, and head of Triphase Accelerator and served on the Triphase board. Triphase had a successful collaboration with Celgene (now BMS) that resulted in advancement of two oncology clinical stage programs (a proteasome inhibitor for glioma and an anti-CD22 ADC for hematological malignancies), as well as several preclinical stage programs. Prior to Triphase, Mo worked at Genentech, Ambit and Centocor/Johnson & Johnson in various roles in R&D. Over his 20 years of drug discovery and development experience, he has helped develop multiple cancer medicines (the anti-IL-6 siltuximab, the antibody drug conjugate ado-trastuzumab amtansine, the hedgehog inhibitor vismodegib, and the FLT3 tyrosine kinase inhibitor quizartinib) and contributed to advancing more than 30 oncology programs from discovery to clinical trials while at Centocor/Johnson & Johnson, Genentech, Ambit, Triphase Accelerator, and AbbVie.

Mo received his BS from California State University, Los Angeles and his PhD from the University of Southern California. He was an Assistant Professor of Research at Wayne State University prior to joining industry.